Misonidazole neuropathy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Misonidazole neuropathy. / Paulson, O B; Melgaard, B; Hansen, H S; Kamieniecka, Z; Køhler, O; Hansen, J M; Pedersen, A G; Tang, X; Trojaborg, W.

In: Acta Neurologica Scandinavica, Vol. 70, No. Suppl 100, 1984, p. 133-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Paulson, OB, Melgaard, B, Hansen, HS, Kamieniecka, Z, Køhler, O, Hansen, JM, Pedersen, AG, Tang, X & Trojaborg, W 1984, 'Misonidazole neuropathy', Acta Neurologica Scandinavica, vol. 70, no. Suppl 100, pp. 133-6.

APA

Paulson, O. B., Melgaard, B., Hansen, H. S., Kamieniecka, Z., Køhler, O., Hansen, J. M., Pedersen, A. G., Tang, X., & Trojaborg, W. (1984). Misonidazole neuropathy. Acta Neurologica Scandinavica, 70(Suppl 100), 133-6.

Vancouver

Paulson OB, Melgaard B, Hansen HS, Kamieniecka Z, Køhler O, Hansen JM et al. Misonidazole neuropathy. Acta Neurologica Scandinavica. 1984;70(Suppl 100):133-6.

Author

Paulson, O B ; Melgaard, B ; Hansen, H S ; Kamieniecka, Z ; Køhler, O ; Hansen, J M ; Pedersen, A G ; Tang, X ; Trojaborg, W. / Misonidazole neuropathy. In: Acta Neurologica Scandinavica. 1984 ; Vol. 70, No. Suppl 100. pp. 133-6.

Bibtex

@article{377c0dd35e3e4e8d915c699047957619,
title = "Misonidazole neuropathy",
abstract = "Neurotoxic side effects of misonidazole with peripheral neuropathy was investigated in two series of patients. The first series consisted of eight patients with carcinoma of the pharynx, larynx or lung who, during treatment with misonidazole, developed peripheral neuropathy dominated by severe sensory symptoms and signs localized mainly to the lower extremities. Misonidazole was given for three to seven weeks in a total dose of 9.6 - 12.6 g/m2 (11 g/m2 or more in four of the patients). The symptoms subsided partially within a few months after cessation of the therapy. Electrophysiological and histological findings indicated axonal neuropathy with loss of large fibres and secondary demyelination. The second series consisted of 70 patients with carcinoma of the pharynx or larynx who, in addition to radiotherapy, were given either placebo or misonidazole over four weeks in a total dose of 11 g/m2. Fourteen patients out of 36 receiving misonidazole (38%) developed peripheral polyneuropathy, mostly in the feet, while this occurred in only two of the 34 patient placebo group.",
keywords = "Aged, Female, Humans, Laryngeal Neoplasms/radiotherapy, Lung Neoplasms/radiotherapy, Male, Middle Aged, Misonidazole/adverse effects, Nitroimidazoles/adverse effects, Peripheral Nerves/pathology, Peripheral Nervous System Diseases/chemically induced, Pharyngeal Neoplasms/radiotherapy",
author = "Paulson, {O B} and B Melgaard and Hansen, {H S} and Z Kamieniecka and O K{\o}hler and Hansen, {J M} and Pedersen, {A G} and X Tang and W Trojaborg",
year = "1984",
language = "English",
volume = "70",
pages = "133--6",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "Suppl 100",

}

RIS

TY - JOUR

T1 - Misonidazole neuropathy

AU - Paulson, O B

AU - Melgaard, B

AU - Hansen, H S

AU - Kamieniecka, Z

AU - Køhler, O

AU - Hansen, J M

AU - Pedersen, A G

AU - Tang, X

AU - Trojaborg, W

PY - 1984

Y1 - 1984

N2 - Neurotoxic side effects of misonidazole with peripheral neuropathy was investigated in two series of patients. The first series consisted of eight patients with carcinoma of the pharynx, larynx or lung who, during treatment with misonidazole, developed peripheral neuropathy dominated by severe sensory symptoms and signs localized mainly to the lower extremities. Misonidazole was given for three to seven weeks in a total dose of 9.6 - 12.6 g/m2 (11 g/m2 or more in four of the patients). The symptoms subsided partially within a few months after cessation of the therapy. Electrophysiological and histological findings indicated axonal neuropathy with loss of large fibres and secondary demyelination. The second series consisted of 70 patients with carcinoma of the pharynx or larynx who, in addition to radiotherapy, were given either placebo or misonidazole over four weeks in a total dose of 11 g/m2. Fourteen patients out of 36 receiving misonidazole (38%) developed peripheral polyneuropathy, mostly in the feet, while this occurred in only two of the 34 patient placebo group.

AB - Neurotoxic side effects of misonidazole with peripheral neuropathy was investigated in two series of patients. The first series consisted of eight patients with carcinoma of the pharynx, larynx or lung who, during treatment with misonidazole, developed peripheral neuropathy dominated by severe sensory symptoms and signs localized mainly to the lower extremities. Misonidazole was given for three to seven weeks in a total dose of 9.6 - 12.6 g/m2 (11 g/m2 or more in four of the patients). The symptoms subsided partially within a few months after cessation of the therapy. Electrophysiological and histological findings indicated axonal neuropathy with loss of large fibres and secondary demyelination. The second series consisted of 70 patients with carcinoma of the pharynx or larynx who, in addition to radiotherapy, were given either placebo or misonidazole over four weeks in a total dose of 11 g/m2. Fourteen patients out of 36 receiving misonidazole (38%) developed peripheral polyneuropathy, mostly in the feet, while this occurred in only two of the 34 patient placebo group.

KW - Aged

KW - Female

KW - Humans

KW - Laryngeal Neoplasms/radiotherapy

KW - Lung Neoplasms/radiotherapy

KW - Male

KW - Middle Aged

KW - Misonidazole/adverse effects

KW - Nitroimidazoles/adverse effects

KW - Peripheral Nerves/pathology

KW - Peripheral Nervous System Diseases/chemically induced

KW - Pharyngeal Neoplasms/radiotherapy

M3 - Journal article

C2 - 6091392

VL - 70

SP - 133

EP - 136

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - Suppl 100

ER -

ID: 275989236